Second and third TNF inhibitors in European patients with axial spondyloarthritis : effectiveness and impact of the reason for switching
(2024) In Rheumatology (United Kingdom) 63(7). p.1882-1892- Abstract
Objective: To investigate real-world effectiveness of tumor necrosis factor inhibitors (TNFi) in patients with axial spondyloarthritis (axSpA) and the association with (i) treatment line (second and third TNFi-series) and (ii) reason for withdrawal from the preceding TNFi [lack of efficacy (LOE) vs adverse events (AE)]. Methods: Prospectively collected routine care data from 12 European registries were pooled. Rates for 12-month drug retention and 6-month remission [Ankylosing Spondylitis Disease Activity Score C-reactive protein inactive disease (ASDAS-ID)] were assessed in second and third TNFi-series and stratified by withdrawal reason. Results: We included 8254 s and 2939 third TNFi-series; 12-month drug retention rates were similar... (More)
Objective: To investigate real-world effectiveness of tumor necrosis factor inhibitors (TNFi) in patients with axial spondyloarthritis (axSpA) and the association with (i) treatment line (second and third TNFi-series) and (ii) reason for withdrawal from the preceding TNFi [lack of efficacy (LOE) vs adverse events (AE)]. Methods: Prospectively collected routine care data from 12 European registries were pooled. Rates for 12-month drug retention and 6-month remission [Ankylosing Spondylitis Disease Activity Score C-reactive protein inactive disease (ASDAS-ID)] were assessed in second and third TNFi-series and stratified by withdrawal reason. Results: We included 8254 s and 2939 third TNFi-series; 12-month drug retention rates were similar (71%). Six-month ASDAS-ID rates were higher for the second (23%) than third TNFi (16%). Twelve-month drug retention rates for patients withdrawing from the preceding TNFi due to AE vs LOE were similar for the second (68% and 67%) and third TNFi (both 68%), while for the second TNFi, rates were lower in primary than secondary non-responders (LOE <26 vs ≥26 weeks) (58% vs 71%, P < 0.001). Six-month ASDAS-ID rates for the second TNFi were higher if the withdrawal reason was AE (27%) vs LOE (17%), P < 0.001, while similar for the third TNFi (19% vs 13%, P = 0.20). Conclusion: A similar proportion of axSpA patients remained on a second and third TNFi after one year, but with low remission rates for the third TNFi. Remission rates on the second TNFi (but not the third) were higher if the withdrawal reason from the preceding TNFi was AE vs LOE.
(Less)
- author
- organization
- publishing date
- 2024-07
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- adverse events, axial spondyloarthritis, effectiveness, lack of efficacy, switching TNF-inhibitors
- in
- Rheumatology (United Kingdom)
- volume
- 63
- issue
- 7
- pages
- 11 pages
- publisher
- Oxford University Press
- external identifiers
-
- pmid:37738257
- scopus:85197586238
- ISSN
- 1462-0324
- DOI
- 10.1093/rheumatology/kead494
- language
- English
- LU publication?
- yes
- id
- 56685a05-501c-40d0-adb3-5b81f3c7d0cd
- date added to LUP
- 2024-10-14 14:09:04
- date last changed
- 2025-06-24 10:27:33
@article{56685a05-501c-40d0-adb3-5b81f3c7d0cd,
abstract = {{<p>Objective: To investigate real-world effectiveness of tumor necrosis factor inhibitors (TNFi) in patients with axial spondyloarthritis (axSpA) and the association with (i) treatment line (second and third TNFi-series) and (ii) reason for withdrawal from the preceding TNFi [lack of efficacy (LOE) vs adverse events (AE)]. Methods: Prospectively collected routine care data from 12 European registries were pooled. Rates for 12-month drug retention and 6-month remission [Ankylosing Spondylitis Disease Activity Score C-reactive protein inactive disease (ASDAS-ID)] were assessed in second and third TNFi-series and stratified by withdrawal reason. Results: We included 8254 s and 2939 third TNFi-series; 12-month drug retention rates were similar (71%). Six-month ASDAS-ID rates were higher for the second (23%) than third TNFi (16%). Twelve-month drug retention rates for patients withdrawing from the preceding TNFi due to AE vs LOE were similar for the second (68% and 67%) and third TNFi (both 68%), while for the second TNFi, rates were lower in primary than secondary non-responders (LOE <26 vs ≥26 weeks) (58% vs 71%, P < 0.001). Six-month ASDAS-ID rates for the second TNFi were higher if the withdrawal reason was AE (27%) vs LOE (17%), P < 0.001, while similar for the third TNFi (19% vs 13%, P = 0.20). Conclusion: A similar proportion of axSpA patients remained on a second and third TNFi after one year, but with low remission rates for the third TNFi. Remission rates on the second TNFi (but not the third) were higher if the withdrawal reason from the preceding TNFi was AE vs LOE.</p>}},
author = {{Linde, Louise and Ørnbjerg, Lykke Midtbøll and Heegaard Brahe, Cecilie and Wallman, Johan Karlsson and Di Giuseppe, Daniela and Závada, Jakub and Castrejon, Isabel and Díaz-Gonzalez, Federico and Rotar, Ziga and Tomšič, Matija and Glintborg, Bente and Gudbjornsson, Bjorn and Geirsson, Arni Jon and Michelsen, Brigitte and Kristianslund, Eirik Klami and Santos, Maria José and Barcelos, Anabela and Nordström, Dan and Eklund, Kari K. and Ciurea, Adrian and Nissen, Michael and Akar, Servet and Hejl Hyldstrup, Lise and Krogh, Niels Steen and Hetland, Merete Lund and Østergaard, Mikkel}},
issn = {{1462-0324}},
keywords = {{adverse events; axial spondyloarthritis; effectiveness; lack of efficacy; switching TNF-inhibitors}},
language = {{eng}},
number = {{7}},
pages = {{1882--1892}},
publisher = {{Oxford University Press}},
series = {{Rheumatology (United Kingdom)}},
title = {{Second and third TNF inhibitors in European patients with axial spondyloarthritis : effectiveness and impact of the reason for switching}},
url = {{http://dx.doi.org/10.1093/rheumatology/kead494}},
doi = {{10.1093/rheumatology/kead494}},
volume = {{63}},
year = {{2024}},
}